1. HOME
2. Research Insight
3. JSR Corporation (Japan) and The Jackson Laboratory (US) are Leading Players in the Patient-Derived Xenograft / PDX Model Market

The PDX model market is projected to reach USD 687 million by 2028 from USD 366 million in 2023, at a CAGR of 13.4% during the forecast period. The key factors driving the growth of the global patient derived xenograft/ PDX model market are the accuracies in drug testing, rising demand in personalized medicine, and the usefulness of PDX models to identify relevant biomarkers for disease diagnosis. However, significant operational costs associated with patient derived xenograft/ PDX model are expected to restrain market growth to a certain extent.

The market for patient derived xenograft/ PDX model is highly fragmented, with key players strategizing to capture the majority of the market. Prominent players in the market are JSR Corporation (Japan), Wuxi Apptec (China), The Jackson Laboratory (US), Charles River Laboratories International, Inc. (US), Taconic Biosciences, Inc. (US), Oncodesign Precision Medicine (France), Inotiv, Inc. (US), Pharmatest Services (Finland), Hera BioLabs (US),  EPO Berlin-Buch GmbH (Germany), Xentech (France), Urosphere (France), Altogen Labs (US), Abnova Corporation (US), Genesis Biotechnology Group (US), Biocytogen Pharmaceuticals Co., Ltd. (China), Creative Animodel (US), BioDuro-Sundia (US), Aragen Life Sciences (India), Shanghai LIDE Biotech Co., Ltd. (China), Certis Oncology Solutions (US), InnoSer (Netherlands), IVRS AB (Sweden), Beijing IDMO Co. Ltd. (China), and Shanghai Chempartner Co. Ltd. (China).

To know about the assumptions considered for the study download the pdf brochure

JSR Corporation (Japan)

JSR Corporation (Japan) is one of the leading player in the overall PDX models market, accounting for the largest market share in 2022. It operates in the market through its subsidiary, Crown Bioscience Inc. JSR Corporation has developed an extensive portfolio of PDX models that encompass a diverse range of cancer types, enabling researchers to perform accurate and predictive preclinical studies. The corporation's commitment to precision and quality shines through in its advanced technology platforms, including HuPrime, HuKemia, and HuGEMM, which offer cutting-edge solutions for drug discovery and development.

The Jackson Laboratory (US)

The Jackson Laboratory (US) is one of the leading players in the PDX models market in 2022. The Jackson Laboratory's repository features a portfolio of over 13,000 strains of genetically defined mice. The company has received many grants which support the development of its PDX models business. Over the last few years, the company has received grants/funds from leading academic institutes and health organizations such as the National Institutes of Health (NIH), and National Cancer Institute (NCI). These grants have helped the company to develop new models and conduct specific studies on the models.

Charles River Laboratories International, Inc. (US)

Charles River Laboratories International, Inc. is a prominent pharmaceutical company that specialies in preclinical and clinical laboratory services. Charles River Laboratories is one of the key players in the field of laboratory animal models, including Patient-Derived Xenografts (PDX). The company offers disease-specific and preconditioned animal models that aid researchers in studying diseases and developing therapeutic interventions. Their expertise spans early preclinical formulation development to clinical and commercial product release, providing tailored scientific solutions to clients.

Related Reports:

Patient-Derived Xenograft / PDX Model Market by Type (Mice, Rat), Implantation Method (Subcutaneous, Orthotopic), Tumor Type (Respiratory, Hematological), Application (Drug Development, Biobanks), End User (Pharma, Biotech, CROs) - Global Forecast to 2028

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]